Recombinant Human Ccn Family Member 1 (CYR61), Active

Name: Recombinant Human Ccn Family Member 1 (CYR61), Active
Brand: Beta LifeScience
SKU: BLC-05972P
Availability: InStock

Collections: Buy cytokines, chemokines, and growth factors for research online, Growth factors and receptors for advanced research, High-quality cytokines for advanced research, High-quality recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Ccn Family Member 1 (CYR61), Active is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 95% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/3T3 cells is less than 3.0 μg/ml, corresponding to a specific activity of >330 IU/mg.
Uniprotkb	O00622
Target Symbol	CYR61
Synonyms	3CH61; CCN 1; CCN family member 1; CCN1; CYR 61; Cyr61; CYR61 protein; CYR61_HUMAN; Cysteine rich angiogenic inducer 61; Cysteine rich heparin binding protein 61; Cysteine-rich angiogenic inducer 61; GIG 1; GIG1; IBP-10; IGF-binding protein 10; Igfbp 10; IGFBP-10; Igfbp10; Insulin like growth factor binding protein 10; Insulin-like growth factor-binding protein 10; Protein CYR61; Protein GIG1
Species	Homo sapiens (Human)
Expression System	E.Coli
Tag	Tag-Free
Complete Sequence	TCPAACHCPL EAPKCAPGVG LVRDGCGCCK VCAKQLNEDC SKTQPCDHTK GLECNFGASS TALKGICRAQ SEGRPCEYNS RIYQNGESFQ PNCKHQCTCI DGAVGCIPLC PQELSLPNLG CPNPRLVKVT GQCCEEWVCD EDSIKDPMED QDGLLGKELG FDASEVELTR NNELIAVGKG SSLKRLPVFG MEPRILYNPL QGQKCIVQTT SWSQCSKTCG TGISTRVTND NPECRLVKET RICEVRPCGQ PVYSSLKKGK KCSKTKKSPE PVRFTYAGCL SVKKYRPKYC GSCVDGRCCT PQLTRTVKMR FRCEDGETFS KNVMMIQSCK CNYNCPHANE AAFPFYRLFN DIHKFRD
Expression Range	25-381aa
Protein Length	Full Length of Mature Protein
Mol. Weight	39.4 kDa
Research Area	Immunology
Form	Liquid or Lyophilized powder
Buffer	0.2 μm filtered citrate buffer solution, 300 mM NaCl, pH 3.0, lyophilized
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.

Target Details

Target Function	Promotes cell proliferation, chemotaxis, angiogenesis and cell adhesion. Appears to play a role in wound healing by up-regulating, in skin fibroblasts, the expression of a number of genes involved in angiogenesis, inflammation and matrix remodeling including VEGA-A, VEGA-C, MMP1, MMP3, TIMP1, uPA, PAI-1 and integrins alpha-3 and alpha-5. CCN1-mediated gene regulation is dependent on heparin-binding. Down-regulates the expression of alpha-1 and alpha-2 subunits of collagen type-1. Promotes cell adhesion and adhesive signaling through integrin alpha-6/beta-1, cell migration through integrin alpha-v/beta-5 and cell proliferation through integrin alpha-v/beta-3.
Subcellular Location	Secreted.
Protein Families	CCN family
Database References	HGNC: 2654 OMIM: 602369 KEGG: hsa:3491 STRING: 9606.ENSP00000398736 UniGene: PMID: 28548552 Serum CCN1 concentrations in Acute Heart Failure patients were significantly increased compared with those in individuals without Acute Heart Failure (237 pg/ml vs. 124.8 pg/ml, p< 0.001). PMID: 30045012 Results show that mRNA and serum expression levels of Cyr61, CTGF, and VEGF in muscle tissues of patients with polymyositis (PM)/dermatomyositis (DM). These data suggest that these genes may be involved in the pathogenesis mainly by affecting the formation of blood vessels and promoting inflammatory response. PMID: 30142763 the CC genotype of CYR61significantly increased the risk of acute myeloid leukemia (AML) in the dominant inheritance and the recessive inheritance. Additionally, it was shown that the rs2297141 and rs6576776 genotypes were associated with AML-M5 and AML-M2, respectively. Our findings indicated that genetic polymorphisms in the CYR61 gene may be considered potential AML risk factors in the Han Chinese population PMID: 30142822 Study describes how cysteine-rich 61 (CCN1) promotes monocyte migration by upregulating monocyte chemoattractant protein-1 (CCL2) expression in osteoblasts in rheumatoid arthritis (RA) disease. CCN1 could serve as a potential target for RA treatment. PMID: 28341837 MiR-365 acts as a tumor suppressor in OS, partly, by targeting CYR61 expression. PMID: 29287201 CCN1 may be involved in the progression of the hepatic cirrhosishepatocellular carcinoma axis through regulating Hepatic stellate cells. PMID: 29286082 study is the first to reveal that Cyr61 is elevated in ALL and promotes cell survival through the AKT/NF-kappaB pathway by up-regulating Bcl-2. PMID: 27725691 PPARgamma agonists may have beneficial effects on the migration and invasion of rheumatoid arthritis-fibroblast-like synoviocytes via the downregulation of Cyr61. PMID: 27456070 CCN1 stimulates CCL20 production in vitro and in vivo, and thus supports the notion that overexpressed CCN1 in hyperproliferating keratinocyte is functionally involved in the recruitment of inflammatory cells to skin lesions affected by psoriasis. PMID: 28602508 Plasma Cyr61 concentration in pulmonary arterial hypertension (PAH)patients was highly increased. Cyr61 could promote pulmonary arterial smooth muscle cells proliferation via AKT pathway, indicating that Cyr61 may play a role in the pathogenesis of PAH. PMID: 28824319 Cyr61 and VEGF expressions were independent prognostic indicators of overall survival and may serve as important prognostic predictors in patients with osteosarcoma. PMID: 28647210 our study suggests that suppression of Cyr61 in cancer stem cell-like cells in PDAC may inhibit tumor cell metastasis after resection of the primary tumor. PMID: 27705906 CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and protecting from anoikis during initial seeding to the lung. PMID: 27911269 Knockdown of CYR61 in gastric cancer AGS cells impairs the cancer cell migration and invasion, suggesting a driver role of CYR61 in metastasis. PMID: 27105510 This study is the first to describe how CCN1 promotes VEGF expression in osteoblasts and increased endothelial progenitor cells angiogenesis in rheumatoid arthritis disease. PMID: 27465842 Two interacting partners of urokinase-type plasminogen activator (uPA) receptor, the cysteine-rich angiogenic inducer 61 (Cyr61) and the Y-box-binding protein 1 (YB-1) were identified and their differential expression demonstrated in the triple-negative breast cancer (TNBC) cells as well as in tumors. PMID: 27286449 collagen II-activated phosphorylated-DDR2 induces CYR61 through activation of transcription factor activator protein 1 (AP-1). The elevated CYR61, in turn, accelerates MMP1 production via ETS1 (ETS proto-oncogene 1). PMID: 27653023 Cyr61 stimulated MMP-3 production in fibroblast-like synoviocytes of rheumatoid arthritis patients. PMID: 27585710 Low CCN1 expression is associated with esophageal cancer. PMID: 29055676 this study found that expression of Cyr61 was higher in the ectopic endometrium than in the eutopic endometrium and that Cyr61 expression in the endometrium was correlated with age, number of natural labors, blood loss, uterine volume, adenomyosis type, and concurrent endometriosis PMID: 27644084 The role of CYR61 in aromatase inhibitors resistance in estrogen receptor positive breast cancer patients PMID: 27113745 CYR61 is a TGF-beta-induced stromal-derived factor that regulates gemcitabine sensitivity in pancreatic ductal adenocarcinoma. PMID: 27604902 These studies support previously unrecognized, cooperative interaction between the CCN1 matricellular protein and canonical TGF-beta1/SMAD3 signaling that promotes lung fibrosis. PMID: 26884454 Our data indicate a potential functional impact of Cyr61 in development and the progression of cervical cancer PMID: 28476813 results highlight both CYR61 and TAZ genes as potential predictive biomarkers for stratification of the risk for development of adenocarcinoma and suggest a potential mechanistic route for Barrett's esophagus neoplastic progression PMID: 27583562 Reduced levels of CCN1 and CCN3, as found in early-onset preeclampsia, could contribute to a shift from invasive to proliferative extravillous trophoblasts and may explain their shallow invasion properties in this disease. PMID: 26744771 Promoter activity was determined as well as CYR61 mRNA and protein expression. PMID: 28322825 Our results not only reveal a novel mechanism illustrating the role of Cyr61 in epidermis pathogenesis but also suggest that therapies targeting Cyr61 may represent a novel strategy in the treatment of psoriasis vulgaris. PMID: 27856305 Results provide evidence that CCN1 can stimulate the proliferation and differentiation of osteoblasts in vitro and contribute to bone remodeling in vivo in myeloma bone disease. PMID: 28035364 these data suggest that the WNT/beta-catenin signaling pathway enhances pancreatic cancer development and malignancy in part via up-regulation of CYR61. PMID: 27889647 CCN1 RNAi reduced the mRNA and protein expression levels of CCN1, Akt and VEGF in the HUVECs (P<0.05). Furthermore, LY294002 reduced the mRNA and protein expression levels of CCN1 in the hypoxic cells (P<0.05). Therefore, CCN1 RNAi may offer a novel therapeutic strategy, which may aid in the treatment of pathological angiogenesis via inhibition of the PI3K/AktVEGF pathway PMID: 27666419 High CYR61 expression is associated with colorectal cancer. PMID: 27743169 Following the treatment of B16 cells with epirubicin and IFN-a, CYR61 levels increased, cell growth was inhibited, and proliferating cell nuclear antigen expression decreased. Thus, CYR61 could become a therapeutic target for malignant melanoma patients with high CYR61 expression. PMID: 27665942 The present study aimed to examine the clinical relevance of NOV along with CYR61 and CTGF in gastric cancer by analysing their transcript levels...the expression of NOV and CYR61 was increased in gastric cancer. The elevated expression of CYR61 was associated with poorer survival. NOV promoted proliferation and invasion of gastric cancer cells PMID: 27633176 Taken together, our results provide novel insights into the possible protective role of 7,8-DHF by activating Cyr61 signaling and suppressing ER stress in hypoxic HK-2 cells which have potential clinical implications for the treatment of AKI. PMID: 28116298 up-regulated in epithelial cells of salivary glands of primary Sjogren's syndrome patients PMID: 26630293 Data show that RNA silencing of CCN family member 1 protein (CCN1) inhibits umbilical vein endothelial cell (HUVEC) proliferation under hypoxic conditions by inhibiting phosphoinositide 3-kinase (PI3K)/AKT protein signaling. PMID: 26459773 Studies indicate that the CYR61 CTGF NOV matricellular proteins (CCN family of proteins) comprises the members CCN1, CCN2, CCN3, CCN4, CCN5 and CCN6 and have been identified in various types of cancer. PMID: 26498181 Results suggest that Cyr61 is induced by EGF through the ERK/CREB signal pathway and that it plays a crucial role in the migration and invasion of anaplastic thyroid cancer cells. PMID: 25773758 CCN1 is an injury response protein that functions not only to restrict fibrosis in the liver, but also to suppress hepatocarcinogenesis by inhibiting EGFR-dependent hepatocyte compensatory proliferation PMID: 26028023 we demonstrate that NF2 negatively controls the invasiveness of Glioblastoma multiforme through YAP-dependent induction of CYR61/CCN1 and miR-296-3p. PMID: 26923924 It promotes cell growth and angiogenesis in cancers through its interaction with several integrins and proved to be an independent prognostic factor for patient survival. PMID: 26201842 c-Src regulates secreted proteins, including the exosomal Cyr61, which are involved in modulating the metastatic potential of triple negative breast cancer cells. PMID: 25980494 Report shows evidence that CCN1 is O-fucosylated at Threonine 242 and that O-fucosylation of CCN1 regulates its secretion. PMID: 26424659 Reactive oxygen species increased c-Jun, a critical member of transcription factor AP-1 complex, and increased c-Jun binding to the AP-1 site of the CCN1 promoter. PMID: 25536346 Overexpression of Cyr61 may induce epithelial-mesenchymal transition and therefore leads to laryngeal squamous- cell carcinoma invasion and metastasis and poor prognosis. PMID: 25854342 Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma PMID: 25620088 Report is first to suggest a relationship between a genetic variant p.R47W in CCN1 and atrial septal defects in humans. PMID: 25135600 SYK is downstream of CYR61 and contributes to CYR61-mediated mitoxantrone resistance. The CYR61-SYK pathway represents a potential target for reducing stroma-induced chemoresistance PMID: 25974135

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.